论文部分内容阅读
目的:探讨n 18F-前列腺特异膜抗原(PSMA)-1007 PET/CT对低前列腺特异抗原(PSA)水平前列腺癌复发的检测价值。n 方法:回顾性分析2018年7月至2019年6月在山西省肿瘤医院行n 18F-PSMA-1007 PET/CT显像的可疑生化复发的低PSA水平(<2.0 μg/L)前列腺癌患者45例(年龄59～74岁)。PSA<0.2 μg/L者4例(因例数较少未纳入统计分析)，0.2 μg/L≤PSA<2.0 μg/L者41例。41例中，0.2 μg/L≤PSA<0.5 μg/L 10例，0.5 μg/L≤PSA<1.0 μg/L 14例，1.0 μg/L≤PSA<2.0 μg/L 17例。检测血清PSA水平2周内对患者行PET/CT检查，并依据美国国立综合癌症网络(NCCN)指南将其分为低～中危组(n n＝12)和高危组(n n＝29)。采用n χ2检验、Fisher确切概率法和Spearman秩相关分析数据。n 结果:中位随访7(4～15)个月，45例患者经病理或随访证实，复发31例，未复发14例。n 18F-PSMA-1007 PET/CT诊断前列腺癌复发的灵敏度为100%(31/31)，特异性为13/14，准确性为97.78%(44/45)。1例PSA<0.2 μg/L患者出现腹膜后淋巴结转移，41例0.2 μg/L≤PSA<2.0 μg/L患者中，31例(75.61%)PET/CT显像至少有1处前列腺癌复发灶，其中局部复发20例，淋巴结转移13例，骨转移14例；PSA水平在0.2 μg/L≤PSA<0.5 μg/L、0.5 μg/L≤PSA<1.0 μg/L、1.0 μg/L≤PSA0.05)。n 18F-PSMA-1007 PET/CT阳性结果与血清PSA值、危险度分组呈正相关(n r值：0.394和0.384，均n P<0.05)。n 结论:18F-PSMA-1007 PET/CT对于低PSA水平的前列腺癌生化复发灶有较高的检测价值。n “,”Objective:To investigate the value of n 18F-prostate specific membrane antigen (PSMA)-1007 PET/CT in the detection of prostate cancer recurrence at low serum prostate specific antigen (PSA) level.n Methods:From July 2018 to June 2019, 45 patients (age: 59-74 years) with suspected biochemical recurrence of prostate cancer with low PSA level (<2.0 μg/L) who underwentn 18F-PSMA-1007 PET/CT examinations in Shanxi Tumor Hospital were retrospectively analyzed. Four patients with PSA<0.2 μg/L were not included in the statistical analysis due to the small sample. Among the remaining 41 patients with 0.2 μg/L≤PSA<2.0 μg/L, 10 were with 0.2 μg/L≤PSA<0.5 μg/L, 14 were with 0.5 μg/L≤PSA<1.0 μg/L, 17 were with 1.0 μg/L≤PSA<2.0 μg/L. PET/CT imaging were performed within 2 weeks after the examination of serum PSA. All patients were divided into low-moderate-risk group (n n=12) and high-risk group (n n=29) according to the National Comprehensive Cancer Network (NCCN) guidelines. n χ2 test, Fisher′s exact test and Spearman rank correlation were used to analyze the data.n Results:Patients were followed up for 7 (4-15) months, and all 45 patients were confirmed by pathology or follow-up. There were 31 patients with recurrence and 14 patients without recurrence. The sensitivity, specificity and accuracy were 100%(31/31), 13/14, 97.78%(44/45)respectively. One patient with PSA<0.2 μg/L presented retroperitoneal lymph node metastasis. Among 41 patients with 0.2 μg/L≤PSA<2.0 μg/L, 31(75.61%) were with at least one recurrent lesion byn 18F-PSMA-1007 PET/CT. There were 20 cases of local recurrence, 13 cases of lymph node metastasis, 14 cases of bone metastasis. The detection efficacies of n 18F-PSMA-1007 PET/CT were 5/10 for patients with 0.2 μg/L≤PSA<0.5 μg/L, 11/14 for those with 0.5 μg/L≤PSA<1.0 μg/L, and 15/17 for those with 1.0 μg/L≤PSA0.05). The positive results ofn 18F-PSMA-1007 PET/CT were positively correlated with serum PSA value and risk group (n r values: 0.394, 0.384, both n P<0.05).n Conclusion:18F-PSMA-1007 PET/CT is a valuable tool for detecting biochemical recurrence of prostate cancer with low PSA level.n